Y Intercept Hong Kong Ltd Makes New $564,000 Investment in BeOne Medicines Ltd. – Sponsored ADR $ONC

Y Intercept Hong Kong Ltd purchased a new position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,328 shares of the company’s stock, valued at approximately $564,000.

Several other institutional investors have also modified their holdings of ONC. Caitong International Asset Management Co. Ltd bought a new position in BeOne Medicines in the 2nd quarter worth approximately $28,000. Farther Finance Advisors LLC purchased a new stake in BeOne Medicines during the second quarter valued at about $39,000. Signaturefd LLC purchased a new position in BeOne Medicines during the 2nd quarter worth approximately $49,000. Parallel Advisors LLC purchased a new stake in BeOne Medicines in the 2nd quarter worth about $59,000. Finally, FNY Investment Advisers LLC acquired a new position in BeOne Medicines in the 2nd quarter valued at approximately $121,000. Institutional investors own 48.55% of the company’s stock.

Insider Activity

In other news, Director Corazon (Corsee) D. Sanders sold 2,665 shares of BeOne Medicines stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $337.00, for a total value of $898,105.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Xiaobin Wu sold 49,858 shares of BeOne Medicines stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $304.16, for a total value of $15,164,809.28. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 157,074 shares of company stock worth $49,396,898. 6.62% of the stock is currently owned by corporate insiders.

BeOne Medicines Stock Performance

Shares of ONC stock opened at $332.36 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.72 and a debt-to-equity ratio of 0.04. The company’s fifty day moving average price is $326.63 and its 200-day moving average price is $287.14. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $170.99 and a 12 month high of $355.30. The stock has a market cap of $36.45 billion, a PE ratio of -192.11 and a beta of 0.31.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.37. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. BeOne Medicines has set its FY 2025 guidance at EPS. On average, equities analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, October 8th. JPMorgan Chase & Co. increased their target price on shares of BeOne Medicines from $345.00 to $385.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 8th. Morgan Stanley raised their target price on BeOne Medicines from $350.00 to $383.00 and gave the company an “overweight” rating in a report on Monday, October 20th. Finally, Barclays initiated coverage on BeOne Medicines in a research note on Thursday, September 18th. They set an “overweight” rating and a $385.00 price target for the company. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $350.18.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.